Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. reports developments as a clinical-stage biotechnology company focused on intravitreal gene therapy for ocular diseases. Its updates center on ixoberogene soroparvovec, or Ixo-vec, a one-time intravitreal candidate for neovascular, or wet, age-related macular degeneration, including ARTEMIS Phase 3 trial communications and clinical or regulatory disclosures.
Recurring news also includes operating and financial results, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), material agreements, capital-structure matters, shareholder and governance disclosures, and corporate transaction communications.
Summary not available.
Summary not available.